补中益气汤加味联合吉西他滨在非肌层浸润性膀胱癌术后中的应用

Clinical Application of Buzhong Yiqi Decoction Combined with Gemcitabine in Postoperative Non-Muscular Invasive Bladder Cancer

目的 探讨补中益气汤加味联合吉西他滨在非肌层浸润性膀胱癌术后的应用价值。方法 选取2022年1月至2024年1月陕西省商洛市中心医院收治的102例非肌层浸润性膀胱癌患者为对象,按随机数字表法分为对照组和观察组,各51例。对照组术后予以吉西他滨治疗,观察组予以补中益气汤联合吉西他滨治疗。评估2组临床疗效、中医证候积分、免疫功能、治疗安全性。结果 观察组有效率高于对照组(P <0.05)。观察组中医证候评分均低于对照组(P <0.05)。治疗后,观察组CD4^(+)、CD3^(+)、CD4^(+)/CD8^(+)高于治疗前,CD8^(+)低于治疗前(P <0.05)。2组不良反应发生率差异无统计学意义(P> 0.05)。结论 补中益气汤加味联合吉西他滨在非肌层浸润性膀胱癌术后应用效果良好,可减轻患者主要中医证候,提高机体免疫功能,治疗安全性良好。

Objective To investigate the value of Buzhong Yiqi Decoction combined with gemcitabine in postoperative treatment of non-muscular invasive bladder cancer.Methods A total of 102 patients with non-muscular invasive bladder cancer who underwent surgical treatment from January 2022 to January 2024 at Shangluo Central Hospital were selected.They were randomly divided into a control group and an observation group,with 51 patients in each group.The control group received gemcitabine treatment after surgery,while the observation group received Buzhong Yiqi Decoction combined with gemcitabine.The clinical efficacy,TCM syndrome scores,immune function,and treatment safety were evaluated in both groups.Results The total effective rate of the observation group was higher than that of the control group(P<0.05).The TCM syndrome scores of the observation group were significantly lower than those of the control group(P<0.05).After treatment,the levels of CD4^(+),CD3^(+),and CD4^(+)/CD8^(+)in the observation group were higher than before treatment,and CD8^(+)levels were lower than before treatment(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05)..Conclusion Buzhong Yiqi Decoction combined with gemcitabine has a good effect in the postoperative application for non-muscular invasive bladder cancer,as it can alleviate the main TCM syndromes,improve immune function,and is safe for treatment.